VVOS insider filings
Vivos Therapeutics, Inc. — 28 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen VVOS transaction legs live →
Insider transaction summary — last 90 days
2026-07-26 to 2026-10-24, from the filings listed below: 4 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Amman Bradford K. — Principal Accounting Officer | 1 | — | — | 2 |
| Huntsman Ronald Kirk — Chief Executive Officer, Director | 1 | — | — | 2 |
| JOHNSON GREGG C — Director | 1 | — | — | 1 |
| SOKOLOW LEONARD J — Director | 1 | — | — | 1 |
Recent insider filings — Vivos Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | SOKOLOW LEONARD J — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | JOHNSON GREGG C — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director | Other (J): 85,910 @ $0.58 · Other (J): 85,910 (derivative) @ $0.58 | EDGAR |
| 2026-08-26 | 4 | Amman Bradford K. — Principal Accounting Officer | Grant/award (A): 250,000 @ $0.41 · Grant/award (A): 150,000 (derivative) @ $0.41 | EDGAR |
| 2026-07-15 | 4 | Skaff Michael C — 10% owner | Purchase (P): 859,166 (derivative) @ $0.58 · Purchase (P): 1,890,164 (derivative) @ $0.58 · Purchase (P): 2,749,330 (derivative) @ $0.58 | EDGAR |
| 2026-04-02 | 4 | Skaff Michael C — 10% owner V-Co Investors 3 LLC — 10% owner | Purchase (P): 1,044,777 @ $1.34 · Purchase (P): 308,848 @ $1.34 · Purchase (P): 429,957 (derivative) @ $1.34 · Purchase (P): 1,783,582 (derivative) @ $1.34 · Purchase (P): 1,783,582 (derivative) @ $1.34 | EDGAR |
| 2024-11-27 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director | Grant/award (A): 315,421 (derivative) @ $2.64 | EDGAR |
| 2024-11-27 | 4 | Amman Bradford K. — Chief Financial Officer | Grant/award (A): 149,533 (derivative) @ $2.64 | EDGAR |
| 2024-06-28 | 4 | Thompson Matthew — Director | Grant/award (A): 4,000 (derivative) @ $2.38 | EDGAR |
| 2024-06-28 | 4 | SOKOLOW LEONARD J — Director | Grant/award (A): 4,000 (derivative) @ $2.38 | EDGAR |
| 2024-06-28 | 4 | Lindsay Mark F. — Director | Grant/award (A): 4,000 (derivative) @ $2.38 | EDGAR |
| 2024-06-28 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director | Grant/award (A): 20,000 (derivative) @ $2.38 | EDGAR |
| 2024-06-28 | 4 | Green Ralph Elias — Director | Grant/award (A): 4,000 (derivative) @ $2.38 | EDGAR |
| 2024-06-28 | 4 | Amman Bradford K. — Chief Financial Officer | Grant/award (A): 15,000 (derivative) @ $2.38 | EDGAR |
| 2024-06-28 | 4 | Krammer Anja B — Director | Grant/award (A): 4,000 (derivative) @ $2.38 | EDGAR |
| 2023-06-20 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director | Purchase (P): 14,000 @ $0.53 | EDGAR |
| 2023-06-20 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director | Purchase (P): 21 @ $0.50 · Purchase (P): 10,000 @ $0.54 · Purchase (P): 5,000 @ $0.53 | EDGAR |
| 2023-06-15 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director | Purchase (P): 10,000 @ $0.49 | EDGAR |
| 2022-12-28 | 4 | SOKOLOW LEONARD J — Director | Grant/award (A): 30,000 (derivative) @ $0.48 | EDGAR |
| 2022-12-28 | 4 | Lindsay Mark F. — Director | Grant/award (A): 30,000 (derivative) @ $0.48 | EDGAR |
| 2022-12-28 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director, 10% owner | Purchase (P): 20,000 @ $0.50 · Grant/award (A): 333,334 (derivative) @ $0.48 · Grant/award (A): 150,000 (derivative) @ $0.48 | EDGAR |
| 2022-12-28 | 4 | Thompson Matthew — Director | Grant/award (A): 30,000 (derivative) @ $0.48 | EDGAR |
| 2022-12-28 | 4 | Green Ralph Elias — Director | Grant/award (A): 30,000 (derivative) @ $0.48 | EDGAR |
| 2022-12-28 | 4 | Amman Bradford K. — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0.48 | EDGAR |
| 2022-12-28 | 4 | Krammer Anja B — Director | Grant/award (A): 30,000 (derivative) @ $0.48 | EDGAR |
| 2022-06-03 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director, 10% owner | Purchase (P): 8,000 @ $2.03 · Purchase (P): 4,000 @ $1.83 | EDGAR |
| 2022-02-28 | 4 | Huntsman Ronald Kirk — Chief Executive Officer, Director | Grant/award (A): 125,000 (derivative) @ $3.27 | EDGAR |
| 2022-02-28 | 4 | Amman Bradford K. — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $3.27 | EDGAR |
Recent 8-K events — Vivos Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-01 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-21 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VVOS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs